Three Firms Aim To Launch Therapies For Hereditary Angioedema In 2008
Lev, which submitted a BLA in July, is vying with Dyax and German firm Jerini to launch drugs next year.
Lev, which submitted a BLA in July, is vying with Dyax and German firm Jerini to launch drugs next year.